Time filter

Source Type

Patent
University of Tokyo and Towa Pharmaceutical Co. | Date: 2017-01-18

The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-1500, and a method for preparing the same.


PubMed | Osaka University, Nagahama Institute of Bio-Science and Technology, Towa Pharmaceutical Co. and Sojo University
Type: Journal Article | Journal: Journal of bioscience and bioengineering | Year: 2016

In recent years, the advent of high-throughput omics technology has made possible a new class of strain engineering approaches, based on identification of possible gene targets for phenotype improvement from omic-level comparison of different strains or growth conditions. Metabolomics, with its focus on the omic level closest to the phenotype, lends itself naturally to this semi-rational methodology. When a quantitative phenotype such as growth rate under stress is considered, regression modeling using multivariate techniques such as partial least squares (PLS) is often used to identify metabolites correlated with the target phenotype. However, linear modeling techniques such as PLS require a consistent metabolite-phenotype trend across the samples, which may not be the case when outliers or multiple conflicting trends are present in the data. To address this, we proposed a data-mining strategy that utilizes random sample consensus (RANSAC) to select subsets of samples with consistent trends for construction of better regression models. By applying a combination of RANSAC and PLS (RANSAC-PLS) to a dataset from a previous study (gas chromatography/mass spectrometry metabolomics data and 1-butanol tolerance of 19 yeast mutant strains), new metabolites were indicated to be correlated with tolerance within certain subsets of the samples. The relevance of these metabolites to 1-butanol tolerance were then validated from single-deletion strains of corresponding metabolic genes. The results showed that RANSAC-PLS is a promising strategy to identify unique metabolites that provide additional hints for phenotype improvement, which could not be detected by traditional PLS modeling using the entire dataset.


Okuda Y.,Towa Pharmaceutical Co. | Okamoto Y.,Towa Pharmaceutical Co. | Irisawa Y.,Towa Pharmaceutical Co. | Okimoto K.,Towa Pharmaceutical Co. | And 2 more authors.
Chemical and Pharmaceutical Bulletin | Year: 2014

The purpose of this study was to investigate the applicability of our newly developed technology (RACTAB® technology) for preparing orally disintegrating tablets (ODTs) containing enteric-coated particles. Tamsulosin hydrochloride (TAM) was used as a model drug contained in the enteric-coated particles. Enteric-coated particles containing TAM (ECP-T) were prepared by spray coating a mixture of TAM with controlled-release materials. ECP-T was then mixed with rapidly disintegrating granules (RDGs), which were prepared using the suspension spray-coating method, and was tableted to form ODTs (ODT RAC). ODTRAC was evaluated for its hardness, thickness, internal structure (X-ray-CT scanning), functional properties (controlled-release profile), and in vivo disintegration time. Since RDGs with micronized ethylcellulose (MEC) increased tablet hardness by increasing the contact frequency between granules, ODTRAC containing ECP-T exhibited high hardness (>50 N) and low friability (<0.5%) with a relatively low compression force. After tableting, the structure of ECP-T in ODTRAC remained intact and no damage was observed on the surface. ECP-T recovered from ODTRAC showed the same dissolution profile of TAM in Japanese Pharmacopoeia (JP) 1st and JP 2nd media as that of intact ECP-T, which indicated that the tableting process did not affect the acid-resistibility of the particle. In addition, ODTRAC rapidly disintegrated in vivo (< 30 s), even at a high compression force (at 9 kN). These findings clearly suggest that RACTAB® technology is a useful approach to prepare ODTs containing enteric-coated particles. © 2014 The Pharmaceutical Society of Japan.


Sugiura T.,University of Shizuoka | Sugiura T.,Towa Pharmaceutical Co. | Uchida S.,University of Shizuoka | Namiki N.,University of Shizuoka
Chemical and Pharmaceutical Bulletin | Year: 2012

Orally disintegrating tablets (ODTs) are useful for improving benefits for patients of various ages. Masking the unpleasant taste of a drug is an important factor in the compliance of patients who take ODTs. We evaluated the taste acceptability effects of various taste-masking methods on bitter famotidine ODTs as a clinical pharmacological study. The following methods were tested to compare taste-masking effects: physical masking by spray-coating famotidine with ethyl cellulose versus organoleptic masking with added sweetener and flavor. The ODT samples were prepared as single or combinations of each taste-masking method using a novel suspension spray-coating method including a placebo. A total of 31 healthy volunteers were enrolled in this randomized, double-blind study and asked to score their bitterness, sweetness and total palate impressions by 100 mm visual analogue scale (VAS). VAS scores were significantly improved by the physical and organoleptic methods as compared to without taste-masked ODTs. Furthermore, the combination of both taste-masking methods was most effective for improving palatability and VAS scores were similar to those of placebo ODTs. The results of this study suggest that different taste-masking mechanisms function cooperatively. © 2012 The Pharmaceutical Society of Japan.


Sasakura D.,Showa Pharmaceutical University | Nakayama K.,Showa Pharmaceutical University | Chikuma T.,Towa Pharmaceutical Co.
Pharmazie | Year: 2015

Process analytical technology is important for the analysis and control of manufacturing processes. Nearinfrared spectroscopy is widely used in various process analytical technologies for the analysis of the chemical componentsof solid dosage forms. Lubrication is an important process carried out before a tablet is produced. In this process, the concentration of lubricant, such as magnesium stearate (StMg), might change for one of many reasons during powder transport, which would be a critical problem such as variation in tablet compressibility and dissolution failure of compressed tablets. Our group investigated the feasibility of the quantitative monitoring of a change in the concentration of StMg in the feeder tube of tableting equipment employing real-time near-infrared spectroscopy.


Yamashita S.,Setsunan University | Kataoka M.,Setsunan University | Higashino H.,Setsunan University | Sakuma S.,Setsunan University | And 7 more authors.
Pharmaceutical Research | Year: 2013

Purpose: To evaluate the time-profile of intragastric fluid volume in humans after intragastric administration of drug solution. Methods: Eight healthy volunteers were intragastrically administered 150 mL of drug solution containing atenolol (non-absorbable marker) and salicylic acid, then, aliquots of gastric fluid (ca. 2 mL) were sampled for 2 h through the catheter. Rate constants for secretion and emptying of the fluid were obtained by fitting the time-course of atenolol concentration to the simple gastric fluid transit model. Absorption of salicylic acid from the stomach was estimated by comparing its gastric concentration with that of atenolol. Results: Kinetic analysis of atenolol concentration in the stomach indicated a rapid emptying of the fluid with an average half-life of 4.2 min. Steady-state intragastric fluid volume in 8 volunteers was estimated as 4-133 mL with an average of 42 mL. Intragastric concentration (normalized by dose) of salicylic acid was always lower than that of atenolol, showing approximately 40% of salicylic acid was absorbed from the stomach before emptying to the intestine. Conclusions: This study provided valuable information on intragastric fluid dynamics and gastric drug absorption in humans to establish a better in vitro-in vivo correlation in oral drug absorption. © 2012 Springer Science+Business Media New York.


Patent
University of Tokyo and Towa Pharmaceutical Co. | Date: 2015-03-09

The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-1500, and a method for preparing the same.


Trademark
Towa Pharmaceutical Co. | Date: 2011-07-01

Pharmaceuticals. Full line of prescription and over-the-counter pharmaceutical preparations for humans. Pharmaceutical goods testing or research.


Trademark
Towa Pharmaceutical Co. | Date: 2010-03-12

Pharmaceuticals. Full line of prescription and over the counter pharmaceutical preparations for humans. Testing or research of pharmaceutical goods or the provision of information related to these services and testing or research of medicine, pharmaceuticals, medical care or healthcare or the provision of information related to these services.


Trademark
Towa Pharmaceutical Co. | Date: 2010-12-03

Pharmaceuticals. Full line of prescription and over-the-counter pharmaceutical preparations for humans. Pharmaceutical product testing and research.

Loading Towa Pharmaceutical Co. collaborators
Loading Towa Pharmaceutical Co. collaborators